The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

Recent clinical studies have revealed the treatment of diabetic patients with sodium glucose co-transporter2 (SGLT2) inhibitors to reduce the incidence of cardiovascular events. Using nicotinamide and streptozotocin (NA/STZ) -treated ApoE KO mice, we investigated the effects of short-term (seven day...

Full description

Bibliographic Details
Main Authors: Yusuke Nakatsu, Hiroki Kokubo, Batmunkh Bumdelger, Masao Yoshizumi, Takeshi Yamamotoya, Yasuka Matsunaga, Koji Ueda, Yuki Inoue, Masa-Ki Inoue, Midori Fujishiro, Akifumi Kushiyama, Hiraku Ono, Hideyuki Sakoda, Tomoichiro Asano
Format: Article
Language:English
Published: MDPI AG 2017-08-01
Series:International Journal of Molecular Sciences
Subjects:
diabetes mellitus
atherosclerosis
SGLT2 inhibitor
luseogliflozin
hyperlipidemia
inflammation
Online Access:https://www.mdpi.com/1422-0067/18/8/1704

Internet

https://www.mdpi.com/1422-0067/18/8/1704

Similar Items